Financial Results for year ended 30 September 2025 and Notice of AGM

09 December 2025, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces its audited results for the year ended 30 September 2025 ("FY25").

Execution of the Group's Innovate Lead Scale strategy across the year has delivered a strong financial performance with 13% revenue growth and a 21% reduction in EBITDA loss. Commercial traction has further accelerated into FY26, resulting in a 27% increase to the order book since the FY25 year-end.        

Financial Highlights:

• Revenues grew 13% to £6.5 million (2024: £5.8 million) reflecting new contract and contract extension wins.

•  Gross margin grew to 49% (2024: 47%) reflecting operational leverage within the business partly offset by an expanded operational footprint in North America designed to support further future growth in this market.

• EBITDA losses reduced 20% to £1.3 million (2024: £1.7 million) reflecting revenue growth in the year of £0.7 million, partly offset by targeted investments designed to sustain and accelerate future revenue growth.

• Closing order book of £13.8m (2024: £15.3 million).  In the two months since the period-end, the order book has grown to £17.7 million (as at 30 November 2025) reflecting a further acceleration of the contract win rate seen in the second half of the year.

• Closing, debt-free, cash of £3.5 million (2024: £1.8 million). Cash was augmented by £3.7 million net of fees from an oversubscribed capital raise completed in Q1 of the financial year end.

• Closing balance sheet value (net assets) of £11.7 million (2024: £9.5 million) that includes long-term assets that will underpin the Group's further expansion.

Operational & Commercial Highlights:

• Successful diversification of revenues with new and existing clients across therapeutic areas, clinical phases and geographies.

• Commercial partnership and collaboration activity increased with large CRO, imaging device manufacturers and clinical data management organisations.

• Expansion of the proprietary IXI™ AI-powered platform into new industry verticals, generating a new revenue stream in blood-based biomarker diagnostic validation.

• Continued scientific and technology innovation equipping IXI™ with novel algorithms to deliver differentiated analysis capabilities, with a particular focus on the Alzheimer's disease and Parkinson's disease markets.

• Access and use rights to the Global Alzheimer's Platform (GAP) BioHermes data set covering 1,000 participants across 30 global sites, and including MRI, PET and Blood Based Biomarker data.

• Expansion of the Group's scientific and operational footprint in North America.

Post Period Highlights:

• £1.2 million combined value clinical trial contract wins - a new blood-based biomarker contract and a contract extension in Alzheimer's disease (15 October 2025).

• £3.5 million global Phase 3 clinical trial contract win in Huntington's disease (17 November 2025).

• Appointment of Professor Michael Weiner and Professor Joanna Wardlaw, two leading global experts in the field of Alzheimer's and cerebrovascular disease as advisors to the Company (01 December 2025).

Bram Goorden, CEO of IXICO, said: "2025 has been a pivotal year for IXICO witnessing a strong return to growth, an extension of our leadership in neuroimaging and promising early progress from the Innovate Lead Scale strategy.  The continued development of scientific capabilities through our next-generation IXI™ platform uniquely places IXICO to deliver impact to biopharma and diagnostics partners, helping accelerate the development of much-needed treatments for neurodegenerative disease.  The commercial momentum experienced in FY25 has continued into the new financial year, and together with our incredible group of people and a clear strategy to advance precision medicine, we enter 2026 with confidence and excitement."

The full 2025 Annual Report and Accounts is available on the Company's website.

Notice of AGM

IXICO announces that its 2026 Annual General Meeting ("AGM") will be held at CCT Venues Smithfield, Two East Poultry Avenue, Smithfield, London EC1A 9PT on 23 January 2026 at 10:30 GMT.  The Notice of AGM will be sent to shareholders on or before 20 December 2025 and at the same time will be made available on the Company's website in accordance with AIM Rule 20.

This announcement contains inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.

For further information please contact:

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.  

The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.